Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Helus PharmaHELP -8.01%34 3-1 Month Momentum % is 69.27% as of Aug. 30, 2026. GuruFocus rates HELP with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,385 Biotechnology companies, Helus Pharma ranks better than 98.48% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-30), Helus Pharma's 3-1 Month Momentum % is 69.27%.
The industry rank for Helus Pharma's 3-1 Month Momentum % or its related term are showing as below:
HELP's 3-1 Month Momentum % is ranked better than 98.48% of 1385
companies
in the Biotechnology industry
Industry Median: -9.14
vs HELP: 69.27
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Helus Pharma 3-1 Month Momentum % Related Terms
HELP vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Helus Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helus Pharma 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helus Pharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Helus Pharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helus Pharma (HELP) has a 3-1 Month Momentum % of 69.27% as of Aug. 30, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Helus Pharma and its competitors. According to the industry distribution chart, Helus Pharma ranks #21 out of 1385 companies in the Biotechnology industry, placing it in the top 1.5%.
Is Helus Pharma's 3-1 Month Momentum % too high?
Helus Pharma's current 3-1 Month Momentum % is 69.27%. Based on the distribution chart, Helus Pharma ranks #21 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Helus Pharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helus Pharma ranks #21 out of 1385 companies for 3-1 Month Momentum %. This places Helus Pharma in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Helus Pharma and its competitors. Helus Pharma's current 3-1 Month Momentum % is 69.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current 3-1 Month Momentum % of 69.27%. The current 3-1 Month Momentum % is 69.27%. Helus Pharma's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Helus Pharma (HELP), the current 3-1 Month Momentum % is 69.27% as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
34GF Score
Get the complete analysis for HELP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HELP has been successfully added to your 
